Guerbet : Résultats semestriels 2026.

Guerbet reported H1 2026 revenue of €379.2M, down 2.2% reported and broadly flat (-0.1%) at constant currency and comparable scope, while EBITDA fell to €30.6M from €46.1M and net income swung to a €32.7M loss from a €1.3M profit. Adjusted EBITDA margin contracted to 9.1% from 12.9%, reflecting €14.3M of exceptional Raleigh remediation costs, while free cash flow deteriorated to -€30.2M and net debt rose to €355.9M, or 5.3x leverage. The group secured covenant waivers and is targeting refinancing by October 31, 2026; it reaffirmed full-year guidance for roughly 8% adjusted EBITDA margin and deeply negative FCF of €50M-€70M.

Analysis

GBT has shifted from an operating-recovery equity into a financing-event equity. The relevant valuation variable through 31 October is not normalized 2027 EBITDA but the refinancing coupon, amortization profile and covenant package: with leverage above 5x, negative cash generation and a meaningful maturity wall in 2028, even a successful deal could transfer material enterprise value to lenders through higher cash interest, mandatory deleveraging or equity-linked terms. The CFO transition during negotiations raises execution and disclosure risk, warranting a liquidity discount beyond the operational issues.

The claimed 2027 normalization requires simultaneous recovery in US manufacturing economics, delivery of transformation savings, and stabilization of China after a go-direct transition. These initiatives can improve gross margin structurally, but the near-term mix is unfavorable: price-led, tender-based China revenue carries lower visibility and potentially lower margin, while quality remediation can create recurring validation, inventory and consulting costs rather than a clean one-off. A further adverse FDA finding would be far more consequential than a modest revenue miss because it would impair lender confidence and refinancing capacity.

The contrarian upside is meaningful only if refinancing is completed without dilution and the Q3 release demonstrates sustained US throughput rather than a temporary catch-up. In that case, a heavily discounted GBT could re-rate on 2027 free-cash-flow normalization; however, the company’s adjusted profitability measure is not yet corroborated by cash conversion. This is a watchlist catalyst, not a long before debt terms are public.

Key Decisions for Investors

• Maintain an underweight/short bias in GBT through the 22 October Q3 update and refinancing deadline; cover on confirmed refinancing with no equity issuance or convertibility and a maturity extension beyond 2028. The key downside catalyst is financing terms that imply cash interest or amortization incompatible with 2027 deleveraging.
• Do not initiate a fundamental long until management discloses the refinancing term sheet and Q3 shows US recovery translating into gross-margin and working-capital improvement. A long is only attractive after evidence that 2027 operating cash flow can exceed maintenance CAPEX and service the revised debt structure.
• For BNP, treat the event as immaterial absent disclosure of material direct credit exposure. Monitor French and European bank disclosures for syndicated-loan participation or provisioning; any unexpected exposure would be a credit-quality headline risk rather than a standalone equity thesis.
• Set alerts for an FDA inspection outcome, refinancing completion before 31 October, and a reduction in leverage below 4.5x. Conversely, another waiver, delayed refinancing, incremental remediation provisions, or a downward revision to 2027 margin expectations falsifies any recovery case and supports maintaining the short.